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Background: It is widely acknowledged that adverse lifestyle behaviours in the population now will place an
unsustainable burden on health service resources in the future. It has been estimated that the combined cost to
the NHS in Wales of overweight and obesity, alcohol and tobacco is in excess of £540 million.
In the current climate of financial austerity, there can be a tendency for the case for prevention efforts to be judged
on the basis of their scope for cost savings. This paper was prompted by discussion in Wales about the evidence
for the cost savings from prevention and early intervention and a resulting concern that these programmes were
thus being evaluated in policy terms using an incorrect metric. Following a review of the literature, this paper
contributes to the discussion of the potential role that economics can play in informing decisions in this area.
Discussion: This paper argues that whilst studies of the economic burden of diseases provide information about
the magnitude of the problem faced, they should not be used as a means of priority setting. Similarly, studies
discussing the likelihood of savings as a result of prevention programmes may be distorting the arguments for
public health.
Prevention spend needs to be considered purposefully, resulting in a strategic commitment to spending. The role
of economics in this process is to provide evidence demonstrating that information and support can be provided
cost effectively to individuals to change their lifestyles thus avoiding lifestyle related morbidity and mortality. There
is growing evidence that prevention programmes represent value for money using the currently accepted
techniques and decision making metrics such as those advocated by NICE.
Summary: The issue here is not one of arguing that the economic evaluation of prevention and early intervention
should be treated differently, although in some instances that may be appropriate, rather it is about making the
case for these interventions to be treated and evaluated to the same standard. The difficulty arises when a higher
standard of cost saving may be expected from prevention and public health programmes.
The paper concludes that it is of vital importance that during times of budget constraints, as currently faced, the
public health budgets are not eroded to fund secondary care budget shortfalls, which are more easily identifiable.
To do so would diminish any possibility of reducing the future burden faced by the NHS of lifestyle-related
illnesses.Background
It is widely acknowledged that adverse lifestyle beha-
viours in the population now will place an unsustainable
burden on health service resources in the future. It is
estimated that the ten leading risk factors for disease are
responsible for 77% of deaths and 51% of disability
adjusted life years (DALYs) in the UK [1]. The main* Correspondence: Janine.Hale@wales.gsi.gov.uk
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tobacco, high blood pressure, high cholesterol, high BMI
and alcohol, together accounting for 41% of the burden.
It has also been estimated that behavioural causes ac-
count for nearly 40% of all deaths in the United States
[2]. In contrast it is argued that medical care has a rela-
tively minor role to play in reducing early deaths [3] and
that a broad programme of prevention aimed at changing
these behaviours may help to reduce this burden [4].
Traditionally, Wales has had an interest in and an em-
phasis on the economics of public health, that even pred. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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Kingdom. The Heartbeat Wales programme, initiated in
1985 as a national demonstration project for reducing
coronary heart disease included economic appraisal [5],
while the economics of health promotion were being
considered in Wales before the publication of the Wan-
less reports that highlighted the need to further develop
the evidence base in this area [6].
The Review of NHS Funding and Performance, five
years after the original Wanless report, stated that the
UK has underperformed in terms of potential life years
lost for some diseases (ischaemic heart disease, cerebro-
vascular and respiratory diseases) when compared to
other countries [7]. Furthermore, with the continuing
rising trend in obesity, results are worse than even the
slow uptake scenario, suggesting that significantly higher
levels of funding will be required to provide the level of
services outlined in the first Wanless review in 2002.
The picture is even starker in Wales, with levels of
smoking, obesity and alcohol abuse high relative to other
countries within the UK.
The economic case for prevention
Reviews and models that have been carried out suggest
that substantial benefits could be realised from system-
atic prevention efforts [8,9]. For example, it has been
estimated that a significant proportion of the past reduc-
tions in coronary heart disease mortality could be attrib-
uted to preventive efforts, with treatment explaining less
of the mortality decline than risk factor changes [10].
In addition to the public health arguments for Govern-
ment intervention in public health policy, the case can
further be made on economic grounds. Economic theory
suggests that governments should intervene in the
provision and delivery of goods and services when the
market fails to provide an adequate supply of them . In
the case of prevention, there are at least three potential
sources of market failure [8]:
– Time inconsistent preferences i.e. the preferences of
an individual may not be consistent over time. An
individual may choose instant gratification over their
long-term interests, such that a commitment made
in the present to behave in a certain way in the
future will be broken when that time in the future
comes;
– Departures from rationality (particularly in young
people). The assumption that people act rationally
(defined as maximising their expected utility) is core
to economic thinking. However, it is recognised that
children and young people in particular often make
choices that may not be in their long-term best
interests - they make lifestyle choices with a short-
term view, even when they are informed of futureconsequences. This could provide a justification for
government intervention, to prevent them from
harming themselves; and
– imperfect information – government intervention in
the provision and production of health information
is justifiable as information itself is a public good
and is thus likely to be undersupplied by the market.
The above market failures justify an explicit govern-
ment role in the prevention of lifestyle-related morbidity
and mortality [8].
Further, the existence of negative externalities,
whereby some of the costs of the lifestyle behaviour may
be borne by other individuals, may also provide justifica-
tion for government intervention in this area. Negative
externalities may arise for example through exposure to
second hand smoke or being a victim of accidents or
anti social behaviour caused by alcohol misuse of others.
Interventions to tackle these can take the form of aware-
ness campaigns to raise knowledge of the impacts of
behaviours on others with a view to changing behaviours
(for example raising awareness of the impacts of second
hand smoke on children), or more direct regulations to
control behaviours to reduce the negative externalities,
as has been seen with the regulations on smoking in
public places.
Making the economic case for prevention, however,
has not always been easy. This paper discusses the differ-
ent types of ‘economic’ arguments that have been put
forward and outlines the role that economics can play in
making decisions about public health spending. The
intention of this paper is to add to discussion surround-
ing appropriate use of economic arguments to support
public health initiatives and is not intended to give a de-
finitive answer. A systematic approach to identifying lit-
erature to inform the paper was taken - although a full
systematic review was not performed – to capture the
range of viewpoints portrayed within the literature, to
supplement views obtained as a result of our experience
in Wales.
Discussion
Costs of lifestyle related illnesses
Whilst cost of illness studies per se are not sufficient in-
formation for allocation of resources, the estimation of
the economic losses or costs associated with a particular
health condition can help to establish the proportion of
government resources that could have been used for
other purposes in the absence of these, preventable, dis-
eases [11]. Cost of illness studies also need to be treated
with a degree of caution as they are often based on esti-
mations and assumptions as the full data set required
often does not exist, and there is no standardised meth-
odology for studies of this nature.
Table 1 Estimated costs of lifestyle related illnesses and
prevalence of those lifestyles in Wales
Risk factor Estimated cost
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reporting smoking at least
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16%
Secondary school pupils reporting
having been drunk 4 or more
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Obesity is a major public health issue with over 500 mil-
lion people worldwide estimated to be obese and nearly
1.5 billion people overweight [12]. While the total im-
pact is currently unknown [13], estimates have clearly
demonstrated that obesity imposes a significant eco-
nomic burden. For example, it was estimated that in
2002 the direct plus indirect costs of obesity and over-
weight in England was £6.6 - £7.4 billion [13]. These fig-
ures have been projected to increase dramatically, with
an estimated additional 11 million more obese adults in
the UK by 2030 adding an additional £1.9-£2 billion an-
nual bill to the healthcare system in treatment of pre-
ventable diseases [14]. An earlier study predicted that
the cost burden of obesity would reach £49.9 billion per
annum in England by 2050, as a consequence of increas-
ing BMI [15], and on the basis of these figures, the likely
cost impact in Wales by this time would be approaching
£3 billion per annum.
Public health action is therefore required to tackle
these trends and narrow inequalities in health [16].
Some believe that overweight and obesity will soon rival
tobacco as the world’s leading cause of preventable early
deaths, with the possibility that the health effects of the
obesity pandemic could outweigh the gains in life ex-
pectancy achieved through reductions in smoking rates
[17].
It is now widely accepted that changing our dietary
habits for the better, alongside an improvement in our
activity levels, will have a major impact in reducing rates
of the chronic diseases [13], thus potentially reducing
the economic burden of preventable illness as a result of
this lifestyle behaviour. It needs to be recognised how-
ever, that to achieve this requires an adequate level of in-
vestment, with a long term commitment to a
multipronged approach, alongside an acceptance that
the payoff on the investment may not be observed for
several years [17].
Smoking
Overall, it was estimated that smoking caused some
109,164 deaths in the UK in 2005, and the direct cost to
the NHS of smoking in the UK was estimated to be £5.2
billion in 2005–6 [18]. Godfrey et al. [19] developed a
model using a cohort of smokers, ex-smokers and non
smokers to estimate the lifetime health care costs and
health consequences of smoking for the population of
England. The model estimated that for a cohort of 1000
men, the difference in lifetime direct health care costs
between smokers and non-smokers was £8.6 million
(£4.1 million when discounted at 3.5%). Furthermore, it
has been estimated that the cost of smoking to the NHS
in Wales in 2007/08 was £386 million, equivalent to
£129 per head and 7 per cent of total healthcareexpenditure in Wales [20]. In addition, 34 million work-
ing days are lost in England and Wales every year [21].
Whilst there is no agreement on the number of deaths
that can be attributed to obesity and physical inactivity
combined, it is clear that these and smoking are the top
behavioural causes of premature death [2].Alcohol
Alcohol is a major cause of disease and injury, account-
ing for 9.2% of the years of life lost or lived with a dis-
ability [22]. It has been estimated that alcohol use
accounts directly for 8,000 potential life-years lost in
Wales and can indirectly be accountable for an add-
itional 5,000 [22]. The annual cost of alcohol harm to
the NHS in England has been estimated as £2.7 billion
[23]. The cost to the NHS in Wales has been estimated
as being between £70 million and £73million [24].
Scarborough et al. [25] estimated the costs to the NHS
in the UK of poor diet, physical inactivity, smoking, alco-
hol and overweight and obesity. They found that poor
diet has the highest impact on budget of the NHS.
Table 1 shows the estimated costs of overweight and
obesity, tobacco and alcohol to the NHS in Wales, along
with the prevalence of these lifestyles. Avoidable lifestyle
related illnesses clearly place major demands on NHS
resources, but it must be remembered that there are also
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Welsh population. Working to change these behaviours
therefore brings benefits not only in terms of potentially
releasing resources that can be used elsewhere in the
NHS, but can also bring improvements to the length
and quality of the lives of Welsh citizens.Cost effectiveness versus cost saving
While studies of the economic burden of diseases can
provide information about the magnitude of the problem
faced, they should not be used as a means of priority set-
ting [28,29]. In order to set priorities for the allocation of
resources, information is also required on many factors,
including the relative cost effectiveness of different inter-
vention strategies [11]. It is also important to avoid the
trap of using such estimates to assume that prevention
strategies will necessarily lead to cost savings, since suc-
cessful prevention programmes also require resources.
It is well-recognised that the evidence base for public
health is not as well developed, particularly with regards
to economic evaluation [4,8]. There is, however, evi-
dence supporting the effectiveness of interventions, even
though the cost effectiveness assessment may not have
been made. Recent work undertaken for the Department
of Health in England outlines that there is effectiveness
evidence for interventions aimed at reducing many of
the lifestyle risk factors, although it may be more diffi-
cult to be conclusive about cost effectiveness in some
areas [30]. It is important to note however, that the un-
availability of strong evidence of effectiveness does not
indicate lack of effectiveness. Suhrcke et al. [8] have
argued that Government has an important role to play
not only in interventions to prevent lifestyle risk beha-
viours, but also in research to further develop the evi-
dence base about what works. In a ranking of
preventative health interventions produced for Health
England, the top 12 all demonstrated cost per QALY fig-
ures below £10,000, and well within the recognised
threshold of cost-effectiveness, with 8 of these poten-
tially being cost saving [31].
Rappange et al. [32] make the point that prevention
has sometimes been promoted as simultaneously im-
proving public health and saving money, but that this is
unlikely to be the case, since any savings made in the
treatment of the preventable disease are likely to be offset
by the treatment costs of an unrelated illness in later life.
The authors suggest that the solution is to include the
treatment cost of those diseases in later life in the eco-
nomic assessment. However, this is not employed within
health technology assessments of ‘curative’ interventions
and to do so only in the assessment of preventive inter-
ventions would be introducing an adverse bias for such
interventions in determining resource allocation.There are also other potential issues with this ap-
proach. Cost effectiveness assessments are usually about
assessing the technical efficiency of a programme,
assessing in terms of achieving a single, narrow object-
ive. To include wider impacts would need cost conse-
quences or cost benefit analyses to be carried out. If
the perspective is going to be widened to include the
costs of treating other illnesses, what about wider
impacts on benefits - do we adjust the QALYs gained
by the preventive intervention to reflect the possibility
of these illnesses in later life? Furthermore, there may
be additional benefits in terms of reductions in risks of
other diseases in addition to the target disease as a re-
sult of a successful public health programme, while
there may also be social diffusion effects. Calculating
and including the cost of future unrelated illnesses
assumes that the treatments themselves and the costs
associated with them remain constant over time. Given
that these may occur well into the future, how realistic
an assumption is this? For example, it has been argued
that “reductions in premature deaths [from reductions
in smoking prevalence] will not necessarily result in
increased health care costs in the future. Improvements
in lifestyle achieved through reduced smoking may,
however, reduce disease and disability in the elderly.
This will place fewer demands on the health services
and release resources for other health needs. In
addition, a reduction in premature deaths will provide
benefits to the NHS through reductions in the loss of
NHS employees and their associated skills and experi-
ence” [5]. This is clearly an area that needs further dis-
cussion in the context of all economic evaluations that
relate to health outcomes.
Barton et al. [9] have used modelling techniques to
demonstrate that a population programme that reduces
cardiovascular events by just 1% could result in signifi-
cant savings for the NHS. This study follows the cur-
rently accepted techniques of economic appraisal and
thus does not capture the costs of possible future ill-
nesses as proposed by Rappange et al. Studies of this na-
ture provide important indications of the potential for
saving costs from avoidable morbidity and mortality, and
also demonstrate the scale of resources that could be
allocated to these preventative programmes before
reaching the likely threshold of cost effectiveness. Even
when the savings that are generated may be outweighed
by the costs of future possible illnesses, it is still worth
preventing (and thus saving expenditure on) avoidable
illnesses to improve the efficiency of the NHS overall.
An important distinction needs to be drawn between
possible savings within a particular disease area and re-
ducing the overall NHS budget. The former are import-
ant and worth pursuing even if the overall effect on the
latter is difficult to prove.
Table 2 Spend on prevention
Spend on Prevention (£ million)
Englanda 5,000
Walesb 280
England and Wales 5,280
a [34].
b [35].
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through the adoption of a social welfare perspective for
the evaluation of public health programmes as suggested
by Weatherly and colleagues [33], this doesn’t entirely
address the point. If different economic evaluations
adopt different perspectives for analysis, how can com-
parisons be made across programmes?
The issue here is not one of arguing that the economic
evaluation of prevention and early intervention should be
undertaken differently, although in some instances that
may be appropriate, rather it is about making the case for
a consistent approach to be employed across all evalua-
tions. It needs to be recognised however, that the applica-
tion of economic evaluation techniques developed and
increasingly recognised as the standard approach for
health care interventions [NICE reference case: http://
www.nice.org.uk/media/B52/A7/TAMethodsGuideUpda-
tedJune2008.pdf], to public health programmes is not ne-
cessarily straightforward [6], and these potential
difficulties need to be given careful consideration in the
interpretation of results. Notwithstanding these issues, a
further difficulty arises when prevention and public
health programmes are viewed as potential sources of
financial savings for the NHS.
Spend on prevention
Butterfield et al. [34] estimated that in 2006/07, the
share of total health expenditure allocated to prevention
and public health in England was just over 5 per cent at
£5 billion, falling to 4 per cent (£3.7 billion) if spend on
pharmaceuticals was excluded.
In Wales, Phillips et al. [35] developed an estimate of
prevention spend with reference to the OECD System of
Health Accounts and the structure used to develop the
estimate produced for England by Health England. This
estimate was based on a number of assumptions that
received a limited amount of validation by “experts”, but
result in an estimate that needs to be used with caution
and particularly if using it for comparisons between
countries and over time. The estimate suggested that in
2008/09 £280 million was spent on prevention and pub-
lic health in Wales, which equates to £94 per head, or
5.23 per cent of the Department for Health and Social
Services budget, falling to 4.11 per cent if spending on
pharmaceuticals was excluded [35].
The conclusion of the report above stated that the sys-
tem of accounts needs to be amended whereby the basic
framework of the OECD Health Accounts is used as the
basis of a system applicable to Wales. Without this
change, establishing an estimate suitable for comparative
purposes between countries and across time would be
very difficult.
The need for such accurate and timely health informa-
tion becomes increasingly important when faced with themarketing efforts of industries selling products that can
be detrimental to health. It has been estimated for ex-
ample, that for every $1 spent by the World Health Or-
ganisation on trying to improve the nutrition of the
world’s population, $500 is spent by the food industry ad-
vertising processed foods [36]. The total advertising
spend in the UK on all types of food, soft drinks and
chain restaurants was estimated to be £727 million in
2003, with 72 per cent (£522 million) of that being spent
on television advertising [37]. Tables 2, 3 and 4 show the
breakdown of the television advertising spend, alongside
household final consumption expenditure. Of additional
concern, advertising on food, chain restaurants and soft
drinks constitutes almost one third of the advertising
seen by children during children’s airtime [38]. Further-
more, it has been estimated that the UK alcohol industry
spends approximately £800 million per annum promot-
ing its products, with other sectors of business also play-
ing a significant part in creating a pro-alcohol
environment [39]. Hastings and Angus also discuss the
detrimental impact of this advertising on children and
young people in particular.
Whilst the figures in Tables 3 and 4 may not seem that
large in comparison to the spend on prevention (Table 2),
this is only a small proportion of the money spent pro-
moting these products. Sponsorship has not been
included above and consideration needs to be given to
the mixed messages that are sent when major sporting
and other high profile events are sponsored by fast food
and confectionary producers. Named sponsors for the
Olympics to be held in London 2012 include for ex-
ample, McDonalds, Cadbury and Coca Cola, with McDo-
nalds being named as the only branded restaurant at the
Olympics venues, and announcing plans to open the
world’s largest McDonalds restaurant in the Olympic
Park [41]. Whilst it has been argued that other food will
be available in unbranded venues, offering choice and
balance, it is the branding that will be seen and the mes-
sages that this sends that needs careful consideration
when decisions such as this are taken.
The balance between prevention and treatment
In the United States only 2 to 5 percent of the total
health budget is allocated to population-wide approaches
to health improvement, despite behavioural choices
being estimated as explaining 40% of premature death
Table 3 UK Advertising expenditure
Category UK Advertising
Expenditure (£ million)
TV advertising – soft drinksc 63
TV advertising – chain restaurantsc 70
TV advertising - confectioneryc 107
TV advertising – prepared/convenience foodsc 128
Advertising spend by UK alcohol industryd 800
c [38].
d [39].
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associated costs [43]. In Germany, seven preventable be-
havioural risk factors have been suggested as accounting
for 60% of Germany’s mortality [8]. It has been argued
however, that despite a shift in many countries towards
a more public health oriented strategy, there is evidence
that even the most attentive countries would be well
served to put a significantly larger proportion of their
health care budgets into public health efforts [3]. Liu
and O’Dougherty [42] suggest that a government can
improve its allocation of resources at the macro level for
financing public health services by regulating the pro-
portion of the health budget that should be allocated to
public health and setting up a budget that is separated
from the overall health budget, although they make no
recommendations as to what the proportion should be.
Improving population health could enhance the prod-
uctivity of the workforce and boost the national econ-
omy, reduce health care expenditures and most
importantly, improve people’s lives [2]. There is, for ex-
ample, increasing evidence of the beneficial health and
economic effects of comprehensive smoke-free public
places legislation [44-48]. It needs to be borne in mind
however, that prevention does not always save money,
but this should not detract from the need to rebalance
health care systems towards disease prevention and
health improvement [3]. The investment in better health
in itself is of value. The rationale behind increasing ex-
penditure on public health is the intrinsic value placedTable 4 Household final consumption expenditure
Category Household Final
Consumption Expenditure
(£ million, 2009 figure)e
Mineral water and soft drinks 7,356
Restaurants and hotels -catering 75,726
Sugar and sweet products 8,666
Alcoholic beverages
Retail 14,890
Restaurants and hotels 26,217
Tobacco 16,356
e [40].on the health it confers on the population, not its mon-
etary savings [3]. Suhrcke et al. [8] argue that prevention
should not be held to a higher standard than medical
care, where cost-saving is not the prime objective. Liu
[49] argues that although there is evidence that alloca-
tion of more resources to primary and preventive care
would improve allocative efficiency, there is no clear
mechanism for achieving the desirable resource shifts.
Daube [50] suggests that public health is the poor rela-
tion in the health system. He suggests that a modest in-
crease in the allocation to prevention would enable
significant advances to be made across a wide range of
public health activity and research areas. It is widely
recognised however, that public health measures are in-
adequately funded, thus undermining their effectiveness
[3]. In a study examining what incentives there are for
NHS managers to look at wider health issues, Hunter
and Marks [51] found that public health resources and
staff are thinly spread and that public health leadership
was missing. Furthermore, this study found that al-
though there was an apparent shift in the rhetoric to-
wards prevention, the incentives in the system were still
all geared towards secondary care, with managers and
indeed governments being preoccupied by the demands
of the acute care sector.
Public health practitioners need to be able to influence
the budget for public health activities in order that the
longer term issues are not omitted in favour of short-
term demands. Maher and Ford [52] argue that espe-
cially in times of economic crises, policy makers and de-
cision makers need effective persuasion when deciding
the allocation of resources, and that the case for invest-
ment in disease prevention and management should be
made in terms of promoting health as a human right
and a mechanism for contributing towards poverty re-
duction and economic stability. This is crucial as public
health resource needs are always in competition with the
needs of clinical services. The latter nearly always take
precedence – treatment of individual patients seems far
more immediate a priority than changes in health status
for the future [53].
Some authors suggest that society may value health
gains from preventive interventions differently to those
achieved from other health interventions, in part due to
the inability to directly identify those that benefit, but
also due to issues of personal responsibility, and that this
may impact on willingness to fund the programmes
[32,54]. This could be argued to strengthen the case for
Government provision of these services, as in the ab-
sence of this provision, these programmes may not be
given any priority at all. Given this however, the appro-
priate level of funding for public health is subject to pol-
itical considerations as those requiring clinical services
are often immediately identifiable, whilst those that will
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Coote [55] suggests that a rebalancing of investment to-
wards prevention is unavoidable, but that the pace of
change will need to be carefully managed to ensure that
there is no public perception that the quality of health
services is in decline as a result. It is clear therefore, that
the economic case for any public health programme is
only one component of the decision making process and
that these other factors also need to be considered.
The inability to reliably identify expenditure on public
health potentially increases the ease with which public
health budgets can be reallocated when budgets are
being reduced, as no systematic monitoring is taking
place [53].
Our Healthy Future [56] renews the Welsh Govern-
ment’s commitment to improve the quality and length of
life and to ensure that everyone in Wales has a fair
chance to lead a healthy life. The aims of Our Healthy
Future include increasing the pace of change in improv-
ing health in Wales and providing the strategic direction
for national and local public health. Within the frame-
work, there are two actions that are particularly pertinent
to this paper:
 Rebalance health and social services to prevention
and early intervention;
 Review spend on prevention and early intervention.
The review of spend will help to address some of the
concerns outlined above, by establishing a definition of
prevention and early intervention that can be tracked
and monitored over time. The main purpose of the re-
view of spend is seen as supporting the rebalancing of
health and social services to prevention and early inter-
vention. A strategic approach to prevention spend is
however still required. The budget for health as a whole
and how that is allocated across different categories
needs to be examined, rather than the case for preven-
tion being made on a programme by programme basis.
Prevention needs to be seen as the responsibility of the
whole health system, not just public health practitioners.
Economic approaches could also make an important
contribution to the work being undertaken to rebalance
health and social services. Programme budgeting and
marginal analysis techniques could help to establish ex-
plicit mechanisms by which transfers could be made be-
tween health and social services and prevention and
early intervention.
Research has been undertaken to explore the use of
economic evaluation techniques in public health, and
preliminary results suggest that cost benefit analysis and
cost utility analysis are the preferred approaches to use
for informing prioritization decisions. The research also
demonstrated that further information was also desirable,for example benchmarks to place net-benefit estimates
from cost-benefit analyses into context [57] while the
challenges and barriers to wider adoption of economic
evaluation techniques in public health require further
consideration and the development of a broader frame-
work for undertaking economic evaluations in preven-
tion and public health per se.Summary
Whilst burden of disease studies make an important
contribution in establishing the size of the problem
being faced, these are only part of the picture and care
needs to be taken to ensure that they don’t receive
more focus than merited. Similarly, discussions around
the potential of prevention to save resources are also
interesting and can be helpful in informing planning,
but the case for prevention should not be made on the
basis of these and these studies should not divert atten-
tion away from the key question that needs to be
addressed, that of the most efficient way of improving
population health.
Prevention spend needs to be considered purposefully,
resulting in a strategic commitment to spending. Studies
demonstrating the size of the problems to be tackled can
help inform this and although this paper has shown that
these are not insignificant, these are not and should not
be the main driver. The existence of market failures is
also important and further strengthens the case for a
strategic commitment to prevention efforts. The role of
economics in this process is to provide evidence demon-
strating that information and support can be provided
cost effectively to individuals to change their lifestyles
thus avoiding lifestyle related morbidity and mortality.
There is growing evidence that prevention programmes
represent value for money using the currently accepted
techniques and decision making metrics such as those
advocated by NICE. Where the evidence of effectiveness
and cost effectiveness exists, the case should be made to
provide that information and support to help individuals
live longer, happier, healthier lives, irrespective of
whether there are long term cost savings for the NHS as
a result.
In an era of limited resources, the challenge in pur-
chasing population health is to find the optimal balance
of resource allocation across the known determinants of
health that will produce the most maintenance or im-
provement for the most people with the resources avail-
able [58]. It is of vital importance that during times of
budget constraints, as currently faced, the public health
budgets are not eroded to fund secondary care budget
shortfalls, which are more easily identifiable. To do so
would diminish any possibility of reducing the future
burden faced by the NHS of lifestyle-related illnesses.
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